Semin Respir Crit Care Med 2019; 40(02): 184-193
DOI: 10.1055/s-0039-1684020
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Multidisciplinary Evaluation in Patients with Lung Disease Associated with Connective Tissue Disease

Athol Wells
1   Interstitial Lung Disease Unit, Department of Imaging, Royal Brompton Hospital, London, United Kingdom
,
Anand Devaraj
2   Department of Imaging, Royal Brompton Hospital, London, United Kingdom
,
Elizabetta A. Renzoni
1   Interstitial Lung Disease Unit, Department of Imaging, Royal Brompton Hospital, London, United Kingdom
,
Christopher P. Denton
3   Department of Rheumatology, Royal Free Hospital, London, United Kingdom
› Author Affiliations
Further Information

Publication History

Publication Date:
28 May 2019 (online)

Abstract

Multidisciplinary diagnosis is now viewed as the diagnostic reference standard in interstitial lung disease (ILD). This process consists of the integration of the evidence base with clinical reasoning in the formulation of a diagnosis and requires input from clinicians, radiologists, and, in selected cases, histopathologists. In ILD associated with connective tissue disease (CTD-ILD), multidisciplinary evaluation is especially helpful when CTD is suspected but cannot be diagnosed using strict criteria. In this context, the integration of systemic clinical data, serologic information, and computed tomography and biopsy findings may allow CTD-ILD to be diagnosed. However, the value of multidisciplinary evaluation in CTD-ILD is not confined to diagnosis. The frequent coexistence of pulmonary processes other than ILD, including pulmonary vascular disease, extrapulmonic restriction, and airways disease, often has a major impact on symptoms and pulmonary function tests (PFTs). In this review, we highlight the value of multidisciplinary discussion (MDD) in reconciling clinical data, PFT, and imaging data in the accurate staging of disease severity, baseline prognostic evaluation, and the identification of progression of ILD. MDD also provides a means to combine the views of respiratory physicians and rheumatologists in formulating a treatment strategy. It is often possible to reach a robust view as to whether management should be driven by systemic disease, pulmonary disease, or both. When treatment needs to be introduced or modified for both systemic and pulmonary reasons, face-to-face discussion facilities the selection of therapeutic agents that are likely to be efficacious for both systemic and pulmonary diseases.

 
  • References

  • 1 Lynch DA, Sverzellati N, Travis WD. , et al. Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. Lancet Respir Med 2018; 6 (02) 138-153 Review
  • 2 Tansey D, Wells AU, Colby TV. , et al. Variations in histological patterns of interstitial pneumonia between connective tissue disorders and their relationship to prognosis. Histopathology 2004; 44 (06) 585-596
  • 3 Bouros D, Wells AU, Nicholson AG. , et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002; 165 (12) 1581-1586
  • 4 Park JH, Kim DS, Park IN. , et al. Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med 2007; 175 (07) 705-711
  • 5 Tsuchiya Y, Takayanagi N, Sugiura H. , et al. Lung diseases directly associated with rheumatoid arthritis and their relationship to outcome. Eur Respir J 2011; 37 (06) 1411-1417
  • 6 Moua T, Zamora Martinez AC, Baqir M, Vassallo R, Limper AH, Ryu JH. Predictors of diagnosis and survival in idiopathic pulmonary fibrosis and connective tissue disease-related usual interstitial pneumonia. Respir Res 2014; 15: 154
  • 7 Kim EJ, Elicker BM, Maldonado F. , et al. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J 2010; 35 (06) 1322-1328
  • 8 Kelly CA, Saravanan V, Nisar M. , et al; British Rheumatoid Interstitial Lung (BRILL) Network. Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics--a large multicentre UK study. Rheumatology (Oxford) 2014; 53 (09) 1676-1682
  • 9 Yunt ZX, Chung JH, Hobbs S. , et al. High resolution computed tomography pattern of usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease: relationship to survival. Respir Med 2017; 126: 100-104
  • 10 Douglas WW, Tazelaar HD, Hartman TE. , et al. Polymyositis-dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med 2001; 164 (07) 1182-1185
  • 11 Ito I, Nagai S, Kitaichi M. , et al. Pulmonary manifestations of primary Sjogren's syndrome: a clinical, radiologic, and pathologic study. Am J Respir Crit Care Med 2005; 171 (06) 632-638
  • 12 Castillo D, Walsh S, Hansell DM. , et al; ERICE ILD working group. Validation of multidisciplinary diagnosis in IPF. Lancet Respir Med 2018; 6 (02) 88-89
  • 13 Walsh SLF, Wells AU, Desai SR. , et al. Multicentre evaluation of multidisciplinary team meeting agreement on diagnosis in diffuse parenchymal lung disease: a case-cohort study. Lancet Respir Med 2016; 4 (07) 557-565
  • 14 Fischer A, Antoniou KM, Brown KK. , et al; “ERS/ATS Task Force on Undifferentiated Forms of CTD-ILD”. An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J 2015; 46 (04) 976-987
  • 15 Luppi F, Wells AU. Interstitial pneumonitis with autoimmune features (IPAF): a work in progress. Eur Respir J 2016; 47 (06) 1622-1624
  • 16 Oldham JM, Adegunsoye A, Valenzi E. , et al. Characterisation of patients with interstitial pneumonia with autoimmune features. Eur Respir J 2016; 47 (06) 1767-1775
  • 17 King Jr TE, Bradford WZ, Castro-Bernardini S. , et al; ASCEND Study Group. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370 (22) 2083-2092
  • 18 Richeldi L, du Bois RM, Raghu G. , et al; INPULSIS Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370 (22) 2071-2082
  • 19 Gibson GJ. Clinical Tests of Respiratory Function. London: Chappell and Hall; 1996: 223-224
  • 20 Wells AU, Hansell DM, Rubens MB, Cailes JB, Black CM, du Bois RM. Functional impairment in lone cryptogenic fibrosing alveolitis and fibrosing alveolitis associated with systemic sclerosis: a comparison. Am J Respir Crit Care Med 1997; 155 (05) 1657-1664
  • 21 Cordier J-F. Organising pneumonia. Thorax 2000; 55 (04) 318-328
  • 22 Burke CM, Glanville AR, Morris AJ. , et al. Pulmonary function in advanced pulmonary hypertension. Thorax 1987; 42 (02) 131-135
  • 23 Goh NS, Hoyles RK, Denton CP. , et al. Short-term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis. Arthritis Rheumatol 2017; 69 (08) 1670-1678
  • 24 Nathan SD, Shlobin OA, Ahmad S, Urbanek S, Barnett SD. Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis. Chest 2007; 131 (03) 657-663
  • 25 Steen VD, Graham G, Conte C, Owens G, Medsger Jr TA. Isolated diffusing capacity reduction in systemic sclerosis. Arthritis Rheum 1992; 35 (07) 765-770
  • 26 Broderick A, Fuortes LJ, Merchant JA, Galvin JR, Schwartz DA. Pleural determinants of restrictive lung function and respiratory symptoms in an asbestos-exposed population. Chest 1992; 101 (03) 684-691
  • 27 Wright PH, Hanson A, Kreel L, Capel LH. Respiratory function changes after asbestos pleurisy. Thorax 1980; 35 (01) 31-36
  • 28 Vincken WG, Elleker MG, Cosio MG. Flow-volume loop changes reflecting respiratory muscle weakness in chronic neuromuscular disorders. Am J Med 1987; 83 (04) 673-680
  • 29 Braun NM, Arora NS, Rochester DF. Respiratory muscle and pulmonary function in polymyositis and other proximal myopathies. Thorax 1983; 38 (08) 616-623
  • 30 Gibson GJ, Pride NB, Davis JN, Loh LC. Pulmonary mechanics in patients with respiratory muscle weakness. Am Rev Respir Dis 1977; 115 (03) 389-395
  • 31 Gould GA, Redpath AT, Ryan M. , et al. Lung CT density correlates with measurements of airflow limitation and the diffusing capacity. Eur Respir J 1991; 4 (02) 141-146
  • 32 Hansell DM, Rubens MB, Padley SPG, Wells AU. Obliterative bronchiolitis: individual CT signs of small airways disease and functional correlation. Radiology 1997; 203 (03) 721-726
  • 33 Wells AU, King AD, Rubens MB, Cramer D, du Bois RM, Hansell DM. Lone cryptogenic fibrosing alveolitis: a functional-morphologic correlation based on extent of disease on thin-section computed tomography. Am J Respir Crit Care Med 1997; 155 (04) 1367-1375
  • 34 Antoniou KM, Margaritopoulos GA, Goh NS. , et al. Combined pulmonary fibrosis and emphysema in scleroderma-related lung disease has a major confounding effect on lung physiology and screening for pulmonary hypertension. Arthritis Rheumatol 2016; 68 (04) 1004-1012
  • 35 Jacob J, Song JW, Yoon HY. , et al. Prevalence and effects of emphysema in never-smokers with rheumatoid arthritis interstitial lung disease. EBioMedicine 2018; 28: 303-310
  • 36 Robbie H, Wells AU, Jacob J. , et al. Visual and automated computed tomography (CT) measures of lung volume loss in idiopathic pulmonary fibrosis (IPF). AJR Am J Roentgenol 2019 ; In press
  • 37 Devaraj A, Wells AU, Meister MG, Corte TJ, Wort SJ, Hansell DM. Detection of pulmonary hypertension with multidetector CT and echocardiography alone and in combination. Radiology 2010; 254 (02) 609-616
  • 38 Shin S, King CS, Puri N. , et al. Pulmonary artery size as a predictor of outcomes in idiopathic pulmonary fibrosis. Eur Respir J 2016; 47 (05) 1445-1451
  • 39 Lettieri CJ, Nathan SD, Barnett SD, Ahmad S, Shorr AF. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 2006; 129 (03) 746-752
  • 40 Kawut SM, O'Shea MK, Bartels MN, Wilt JS, Sonett JR, Arcasoy SM. Exercise testing determines survival in patients with diffuse parenchymal lung disease evaluated for lung transplantation. Respir Med 2005; 99 (11) 1431-1439
  • 41 Leuchte HH, Baumgartner RA, Nounou ME. , et al. Brain natriuretic peptide is a prognostic parameter in chronic lung disease. Am J Respir Crit Care Med 2006; 173 (07) 744-750
  • 42 Wells AU, Cullinan P, Hansell DM. , et al. Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 1994; 149 (06) 1583-1590
  • 43 Marie I, Hachulla E, Chérin P. , et al. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum 2002; 47 (06) 614-622
  • 44 Tashkin DP, Elashoff R, Clements PJ. , et al; Scleroderma Lung Study Research Group. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354 (25) 2655-2666
  • 45 Ley B, Ryerson CJ, Vittinghoff E. , et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 2012; 156 (10) 684-691
  • 46 Ryerson CJ, Vittinghoff E, Ley B. , et al. Predicting survival across chronic interstitial lung disease: the ILD-GAP model. Chest 2014; 145 (04) 723-728
  • 47 Goh NS, Desai SR, Veeraraghavan S. , et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008; 177 (11) 1248-1254
  • 48 Moore OA, Goh N, Corte T. , et al. Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease. Rheumatology (Oxford) 2013; 52 (01) 155-160
  • 49 Khanna D, Nagaraja V, Tseng CH. , et al. Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis-associated interstitial lung disease trials. Arthritis Res Ther 2015; 17: 372
  • 50 Jacob J, Hirani N, van Moorsel CHM. , et al. Predicting outcomes in rheumatoid arthritis related interstitial lung disease. Eur Respir J 2019; 53 (01) 1800869 PubMed
  • 51 Wang X, Lou M, Li Y. , et al. Cardiovascular involvement in connective tissue disease: the role of interstitial lung disease. PLoS One 2015; 10 (03) e0121976
  • 52 Latsi PI, du Bois RM, Nicholson AG. , et al. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 2003; 168 (05) 531-537
  • 53 Collard HR, King Jr TE, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003; 168 (05) 538-542
  • 54 Flaherty KR, Mumford JA, Murray S. , et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003; 168 (05) 543-548
  • 55 American Thoracic Society. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000; 161 (2 Pt 1): 646-664
  • 56 Solomon JJ, Chung JH, Cosgrove GP. , et al. Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J 2016; 47 (02) 588-596
  • 57 Moore OA, Proudman SM, Goh N. , et al. Quantifying change in pulmonary function as a prognostic marker in systemic sclerosis-related interstitial lung disease. Clin Exp Rheumatol 2015; 33 (04) (Suppl. 91) S111-S116
  • 58 Richeldi L, Ryerson CJ, Lee JS. , et al. Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis. Thorax 2012; 67 (05) 407-411
  • 59 Goldin JG, Kim GHJ, Tseng CH. , et al. Longitudinal changes in quantitative interstitial lung disease on computed tomography after immunosuppression in the Scleroderma Lung Study II. Ann Am Thorac Soc 2018; 15 (11) 1286-1295
  • 60 Schiff M, Beaulieu A, Scott DL, Rashford M. Mycophenolate mofetil in the treatment of adults with advanced rheumatoid arthritis: three 24-week, randomized, double-blind, placebo- or ciclosporin-controlled trials. Clin Drug Investig 2010; 30 (09) 613-624
  • 61 Andersson H, Sem M, Lund MB. , et al. Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease. Rheumatology (Oxford) 2015; 54 (08) 1420-1428
  • 62 Daoussis D, Liossis SN, Tsamandas AC. , et al. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford) 2010; 49 (02) 271-280